Trial Profile
PHASE 1B/2 STUDY OF PF-04136309 IN COMBINATION WITH GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs PF 4136309 (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms CCR2i
- Sponsors Pfizer
- 12 Jul 2019 Safety and efficacy results published in the Investigational New Drugs.
- 05 Jan 2018 Status changed from completed to discontinued.
- 02 Nov 2017 Status changed from active, no longer recruiting to completed.